Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Synovial sarcoma (SS) remains a challenging malignancy with limited targeted therapy options.
• The mechanistic target of rapamycin (mTOR) pathway is implicated in SS pathogenesis.
• RAD001, an mTOR inhibitor, has shown potential but with variable efficacy.

Purpose of the Study:

• To investigate the efficacy of the mTOR inhibitor RAD001 as a novel therapy for synovial sarcoma.
• To identify mechanisms of resistance to mTOR inhibitors in SS.
• To explore combination strategies to overcome resistance and improve therapeutic outcomes.

Main Methods:

• In vitro studies using synovial sarcoma cell lines to assess RAD001 sensitivity.
• Phospho-receptor tyrosine kinase (RTK) array analysis to identify activated signaling pathways.
• In vivo xenograft models to evaluate the efficacy of combined RAD001 and pazopanib treatment.

Main Results:

• RAD001 demonstrated significant anti-tumor activity, but sensitivity varied across SS cell lines.
• High sensitivity correlated with c-MET phosphorylation, while PDGFRα activation was associated with resistance.
• Combined treatment with RAD001 and the PDGFR inhibitor pazopanib exhibited anti-tumor effects in resistant xenograft models.

Conclusions:

• Activated receptor tyrosine kinases (RTKs) like PDGFRα can confer resistance to mTOR inhibitors in synovial sarcoma.
• Evaluating RTK activation in clinical samples may predict patient response to mTOR inhibitors.
• Combination therapy with RAD001 and pazopanib offers a promising strategy for treating resistant synovial sarcoma, paving the way for personalized treatment approaches.